Company
Sekisui XenoTech’s mission is to lead collaborations with the world’s principal researchers and scientific experts, advancing life-enhancing therapies with unparalleled insight and interpretation through high value products and bespoke services.
Our vision is to be the world's foremost facilitator in the pursuit of life-enhancing therapies.
About Sekisui XenoTech
Sekisui XenoTech was founded to provide scientists and pharmaceutical researchers with the finest tools and resources needed to advance the development of safer drugs. We employ strict quality standards following well-developed and time-tested standard operating procedures to ensure the highest level of performance, saving you valuable time and money. It's through this unwavering dedication to sound science that we make sure our work is done right - the first time. At Sekisui XenoTech, we are committed to satisfying not just your company's needs, but also the expectations of the FDA or any global regulatory agency that might review our reports and scientific opinions.
25 Years of ADME / DMPK / DDI Expertise
Our wealth of experience and expertise, our understanding of the latest regulatory guidance and industry whitepapers and our commitment to research and development has made Sekisui XenoTech a trusted partner and expert consultant to
39 of the top 40 pharmaceutical companies worldwide, as well as numerous biotech; small, medium and virtual pharma; and other organizations.
Sekisui XenoTech's strong reputation for high quality
in vitro drug metabolism studies attracted the attention of Sekisui, who became our parent company in August, 2008. This alignment has allowed us to offer a much wider range of services to accelerate drug development, including the areas of
in vivo ADME,
Drug Metabolism,
Transporters and
Drug-Drug Interactions.
As a premier provider of
in vitro drug metabolism and drug-drug interaction studies to pharmaceutical companies worldwide, we have unparalleled experience in evaluating drug candidates as substrates, inhibitors and inducers of drug-metabolizing enzymes. Core capabilities include
Enzyme Inhibition,
Enzyme Induction,
Drug Metabolism,
Drug Transport and
Analytical Services.
Sekisui XenoTech's core contract research capabilities:
In vivo ADME research service offerings through Sekisui:
Sekisui XenoTech's core research test system products:
Distributed products:
Or Call 1-877-588-7530
(+1.913.438.7450 If Outside North America)
